D.E. Shaw & Co
TCRX icon

D.E. Shaw & Co’s TScan Therapeutics TCRX Stock Holding History

D.E. Shaw & Co’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$323K Buy
319,587
+250,160
+360% +$267K ﹤0.01% 4048
2025
Q4 		$69.4K Buy
+69,427
New +$100K ﹤0.01% 4419

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

D.E. Shaw & Co's TCRX Position: Q1 2026 in Review

D.E. Shaw & Co increased its TScan Therapeutics (TCRX) stake by 360% in Q1 2026, buying an estimated $267K and bringing the position to 319,587 shares worth $323K. The position accounts for ﹤0.01% of the portfolio, ranked #4048.

D.E. Shaw & Co first reported a position in TCRX in Q4 2025 and has held it in 2 quarters since. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

  • D.E. Shaw & Co held 319,587 shares of TScan Therapeutics worth $323K as of Q1 2026.
  • D.E. Shaw & Co bought 250,160 TScan Therapeutics shares in Q1 2026, an estimated $267K.
  • TScan Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #4048 holding.
  • D.E. Shaw & Co first reported a position in TScan Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.